Compare VALN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALN | CDNA |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 855.8M | 1.0B |
| IPO Year | 2021 | 2014 |
| Metric | VALN | CDNA |
|---|---|---|
| Price | $10.30 | $20.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $15.75 | ★ $26.67 |
| AVG Volume (30 Days) | 19.5K | ★ 723.7K |
| Earning Date | 11-20-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | $211,089,992.00 | ★ $357,998,000.00 |
| Revenue This Year | $3.64 | $14.47 |
| Revenue Next Year | $12.23 | $11.35 |
| P/E Ratio | ★ N/A | $16.81 |
| Revenue Growth | 13.48 | ★ 14.46 |
| 52 Week Low | $4.56 | $10.96 |
| 52 Week High | $12.25 | $25.55 |
| Indicator | VALN | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 56.46 |
| Support Level | $9.62 | $19.48 |
| Resistance Level | $10.32 | $21.49 |
| Average True Range (ATR) | 0.30 | 1.18 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 62.50 | 76.57 |
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.